EZH2 and ovarian cancer: On the other hand, enhancer of zeste homolog 2 (EZH2) promotes LPAR1 expression by inhibiting micro RNA-139 (miR-139) expression—an LPAR1 targeting miRNA—through inducing H3K27me3 methylation [81], whilst overexpression of miR-367 downregulates LPAR1 levels to inhibit ovarian cancer cell proliferation, invasion and tumour-induced angiogenesis [82].